Pharmaceuticals Europe

Europe Hyperuricemia Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Europe Hyperuricemia Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Europe · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $493.6 Mn Placeholder estimate
Estimate 2025 $520.2 Mn 18.9% of the global market
Projected 2034 $835.2 Mn 60.5% Adds $314.9 Mn over 9 forecast years
CAGR 2025–2034 5.4% Faster than 31% of 180 Pharmaceuticals markets here
Key players 5
  • Europe is 18.93% of the global market.
  • Among regions, the largest is North America at $1.53 Bn.
  • Fastest growing: Africa at 8.9% a year.
  • Europe ranks 3rd of 6 by size among regions.

Market size projection

Europe

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$314.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Hyperuricemia Drugs Market market size by year, Europe
YearMarket sizeChange that yearSince 2025
2024 (estimate) $493.6 Mn — —
2025 (base) $520.2 Mn +$26.7 Mn —
2026 (forecast) $548.3 Mn +$28.1 Mn +5.4%
2027 (forecast) $577.9 Mn +$29.6 Mn +11.1%
2028 (forecast) $609.2 Mn +$31.2 Mn +17.1%
2029 (forecast) $642.0 Mn +$32.9 Mn +23.4%
2030 (forecast) $676.7 Mn +$34.7 Mn +30.1%
2031 (forecast) $713.3 Mn +$36.5 Mn +37.1%
2032 (forecast) $751.8 Mn +$38.5 Mn +44.5%
2033 (forecast) $792.4 Mn +$40.6 Mn +52.3%
2034 (forecast) $835.2 Mn +$42.8 Mn +60.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Europe Hyperuricemia Drugs Market Analysis at a glance
Market size, 2025$520.2 Mn placeholder estimate
Forecast, 2034$835.2 Mn placeholder estimate
Growth (CAGR), 2025–20345.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, indication and end user (see all)
Key playersTakeda Pharmaceutical Company Ltd, Amgen Inc., Teijin Pharma, Fuji Yakuhin, Arthrosi Therapeutics (see all)
Regulator in EuropeEMASource: European Medicines Agency. Checked 14 Nov 2026.
Active clinical trials6 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Europe Hyperuricemia Drugs Market Analysis Executive Summary

Hyperuricemia drugs lower high uric acid in the blood, which can cause gout and kidney stones and is linked to heart and kidney disease.

Key segments of the hyperuricemia Drugs market include drug class (Xanthine Oxidase Inhibitors, URAT1 Inhibitors and Recombinant Uricase) and indication (Gout, Chronic Kidney Disease and Tumor Lysis Syndrome).

Bar chart: Europe Hyperuricemia Drugs market size, 2024–2034, placeholder estimates. $493.6 Mn in 2024, $520.2 Mn in 2025 and $835.2 Mn in 2034, 5.4% CAGR.
Europe Hyperuricemia Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Europe Hyperuricemia Drugs Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the hyperuricemia Drugs market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the hyperuricemia Drugs market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the hyperuricemia Drugs market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Hyperuricemia Drugs Market in Europe

The hyperuricemia Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Hyperuricemia Drugs Market in Europe

Hyperuricemia Drugs in Europe: rules, payment and research

In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).⁠[1] In the countries we cover here, medicines are approved by ANSM (France)⁠[2], BfArM (Germany)⁠[3], AIFA (Italy)⁠[4], Ministry of Health (Russia)⁠[5], AEMPS (Spain)⁠[6] and MHRA (UK)⁠[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.⁠[8] ClinicalTrials.gov lists 6 studies on Hyperuricemia Drugs that are recruiting, active or about to start in Europe.⁠[9]

[1] European Medicines Agency. Checked 14 Nov 2026.

[2] ANSM, French medicines agency. Checked 14 Nov 2026.

[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[4] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.

[5] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.

[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[8] European Commission, health technology assessment. Checked 14 Nov 2026.

[9] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for hyperuricemia Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Hyperuricemia Drugs right now, from free public sources.

Clinical trials

6 active trials in UK, Germany, France, Italy, Spain and Russia

Recruiting, about to start, or running now. Counted across the 6 countries we report on in Europe.

Top trial sponsors (worldwide)

  1. Crystalys Therapeutics 2 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Shanton Pharma 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Hyperuricemia Drugs in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Hyperuricemia Drugs market in Europe?
Placeholder estimate: about $520.2 Mn in 2025, rising to about $835.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Hyperuricemia Drugs market in Europe growing?
Placeholder estimate: about 5.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Hyperuricemia Drugs market report cover?
The report splits the market by drug class (Xanthine Oxidase Inhibitors, URAT1 Inhibitors, Recombinant Uricase), indication (Gout, Chronic Kidney Disease, Tumor Lysis Syndrome) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Hyperuricemia Drugs market?
Key players include Takeda Pharmaceutical Company Ltd, Amgen Inc., Teijin Pharma, Fuji Yakuhin and Arthrosi Therapeutics.
What is driving the Hyperuricemia Drugs market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the hyperuricemia Drugs market.
Who regulates Hyperuricemia Drugs in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on Hyperuricemia Drugs are running in Europe?
6 studies are recruiting, active or about to start in Europe, counted across the 6 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on Hyperuricemia Drugs?
PubMed lists 2,548 papers on Hyperuricemia Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Europe

See all

Related on kidney health

See the topic